STERIS plc (STE) Stock Price
STERIS plc Price
Revenue has compounded at 8.8% per year over the past 19 years to 5.94 B USD. Earnings per share have grown at 10.1% per year over the last 19 years. STERIS plc's net margin stands at 13.2%, up from 5.8% several years earlier. STERIS plc currently offers a dividend yield of about 1.15%. The payout ratio is around 93% of earnings. The dividend has grown at 13.5% per year over the past 19 years. Analysts set a median price target of 270.00 USD, implying 26.7% above the current price. Of 16 analysts, 11 rate the stock a buy — an overall Buy consensus.
STERIS plc stock price
STERIS plc business model & stock analysis
Frequently asked questions about STERIS plc
The business model of Steris plc revolves around providing innovative and comprehensive solutions in the healthcare industry. As a global leader, Steris plc focuses on offering products and services that enhance infection prevention, sterilization, and surgical efficiency. With a wide range of offerings including equipment, consumables, and software solutions, Steris plc aims to improve patient outcomes and increase operational productivity for hospitals and healthcare facilities worldwide. Their dedication to advanced technologies and patient safety has earned them a strong reputation in the industry.
Steris plc is primarily active in the healthcare industry. As a global leader, Steris provides innovative solutions and products focused on infection prevention, cleaning, and sterilization for healthcare facilities. With a wide range of offerings, Steris caters to hospitals, ambulatory surgical centers, pharmaceutical companies, and other healthcare institutions. By leveraging its expertise and advanced technologies, Steris aims to enhance patient safety, improve operational efficiency, and support healthcare professionals in delivering high-quality care.
The main competitors of Steris plc in the market include companies such as Johnson & Johnson, 3M Company, and Cantel Medical Corp. These companies operate in the same sector as Steris plc and provide similar products and services. However, Steris plc stands out due to its strong position in the market, diverse product portfolio, and robust customer base. With its innovative solutions and consistent focus on customer satisfaction, Steris plc continues to stay ahead of its competitors in the industry.
Steris plc is a leading global provider of infection prevention and surgical products, services, and technologies. The company was founded in 1985 as Innovative Medical Technologies and later changed its name to Steris Corporation. In 2015, Steris Corporation merged with Synergy Health plc to become Steris plc. With a rich history spanning over three decades, Steris plc has been dedicated to advancing healthcare and related industries. The company offers a wide range of solutions, including sterilization systems, surgical tables, detergents, and disinfectants. Steris plc has established itself as a trusted name in the medical and life sciences sectors, constantly striving to enhance patient safety and improve healthcare outcomes.
Steris plc, a leading company in the medical technology field, has achieved several significant milestones over the years. One noteworthy accomplishment is the acquisition of Synergy Health, which allowed Steris plc to expand its product portfolio and strengthen its global presence. Additionally, the company made strides in research and development, launching innovative solutions such as the Sterrad NX and System 1E, which revolutionized sterilization practices in healthcare settings. Steris plc also gained recognition for its commitment to quality, receiving ISO 9001 certification for its manufacturing facilities. These milestones highlight Steris plc's dedication to delivering advanced and reliable medical technology solutions to its customers worldwide.
Steris plc is primarily present in several countries and regions around the world. As a global company, Steris plc has a significant presence in the United States, where it is headquartered. It also operates in various regions including Europe, Asia, and Latin America. The company's international presence allows it to serve a diverse range of customers and expand its market reach. With a strong focus on providing innovative infection prevention and sterilization solutions, Steris plc continues to establish itself as a leader in the healthcare and life sciences industries worldwide.
Steris plc is a global leader in infection prevention, sterilization, and surgical products and services. The values and corporate philosophy that define Steris plc revolve around their commitment to enhancing healthcare safety and improving the quality of patient care. The company focuses on delivering innovative solutions that enable healthcare professionals to create a safer environment for their patients. Steris plc consistently strives for excellence, constantly innovating and improving to meet the evolving needs of healthcare providers worldwide. With a strong emphasis on integrity, collaboration, and customer-centricity, Steris plc is dedicated to driving positive changes in healthcare practices and improving outcomes for patients.
Analysts currently set an average price target of 271.33 USD for the STERIS plc stock (median: 270.00 USD), implying +27.3 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the STERIS plc stock: 11 recommend buying, 5 holding and 0 selling.
Converted at the current exchange rate, the STERIS plc share trades at 190.16 EUR (213.13 USD).
The STERIS plc share (STE) is listed on 3 stock exchanges, including: NYSE (STE), London (0XI8.L), Frankfurt (2TG.F).
Steris plc is a globally leading company in the field of sterilization and disinfection of medical instruments and facilities. Its business model is based on three main divisions: Healthcare Products, Healthcare Specialty Services, and Life Sciences. Steris offers a wide range of products and services to ensure effective sterilization and disinfection in the medical field. The company is committed to continuous improvement and innovation to meet customer needs. It also prioritizes sustainability and works closely with customers to develop tailored solutions.
The revenue of STERIS plc is 5.94 B USD. This figure is based on current financial data and reflects the company's business performance.
The profit of STERIS plc is 785.10 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of STERIS plc is currently 26.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the STERIS plc stock.
The price-to-sales ratio (P/S) of STERIS plc is currently 3.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the STERIS plc stock.
The Eulerpool Quality Score for STERIS plc is 8/10.
The ISIN of STERIS plc is IE00BFY8C754. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of STERIS plc is A2PGLV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of STERIS plc is STE. The ticker symbol is used to trade STERIS plc shares on the stock exchange.
STERIS plc stock
All fundamentals and in-depth analysis of STERIS plc
Our stock analysis for STERIS plc stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of STERIS plc. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.